Abbott Laboratories (ABT)

ABT (NYSE:Drugs)
$44.25
pos +0.09
+0.20%
Today's Range: 43.99 - 44.43 | ABT Avg Daily Volume: 4,930,400
Last Update: 11/26/14 - 4:00 PM EST
Volume: 2,876,740
YTD Performance: 15.44%
Open: $44.16
Previous Close: $44.16
52 Week Range: $35.65 - $44.77
Oustanding Shares: 1,505,790,586
Market Cap: 66,495,712,278
6-Month Chart
TheStreet Ratings Grade for ABT
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 7
Moderate Buy 4 4 4 3
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.79 1.84 1.84 1.83
Latest Dividend: 0.22
Latest Dividend Yield: 1.99%
Dividend Ex-Date: 10/10/14
Price Earnings Ratio: 35.05
Price Earnings Comparisons:
ABT Sector Avg. S&P 500
35.05 34.80 25.98
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.39% 16.23% 70.03%
GROWTH 12 Mo 3 Yr CAGR
Revenue -45.20 -0.38 -0.15
Net Income -56.80 -0.48 -0.20
EPS -56.80 -0.45 -0.18
Earnings for ABT:
EBITDA 4.35B
Revenue 21.85B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.69 $0.45 $2.26 $2.34
Number of Analysts 9 6 11 12
High Estimate $0.69 $0.49 $2.28 $2.49
Low Estimate $0.68 $0.41 $2.26 $2.16
Prior Year $0.58 $0.41 $2.01 $2.26
Growth Rate (Year over Year) 18.39% 9.35% 12.66% 3.11%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
I really like a couple of names despite the uncertainty.

Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Bullish
Oct 29, 2014 | 6:31 AM EDT
ABT was upgraded to Buy, Deutsche Bank said. $54 price target. Management has the company poised to deliver sustained growth. 
There may be a wave of consolidation.
And don't try to catch every move.
Bearish
Jul 21, 2014 | 7:59 AM EDT
ABT 2015E-2018E EPS estimates lowered 7-10%, Jefferies said. Buy rating. Estimates reflect the divestiture of the developed market EPD ...

This Morning's Market Setup Real Money Pro($)

Where it began.
Bullish
May 19, 2014 | 8:18 AM EDT
ABT was upgraded from Neutral to Outperform, Credit Suisse said. $46 price target. Company is more attractive, following the CFR acquis...
Update
May 08, 2014 | 7:08 AM EDT
Deutsche Bank Healthcare Conference
Bullish
Mar 19, 2014 | 7:29 AM EDT
ABT lowered its number, Jefferies said. Pricing pressure in EPD, MD pricing/volume pressurse and FX exposure. $45 price target. Buy rat...

Columnist Conversations

Kass:
Monitise has announced the sale of additional stock to Telefonica, Santander and Master Card. Expands relation...
Lang:
Lights, Camera, ACTION! This move lately in GPRO has been stellar, up nearly 12% over the past couple of sess...
For just under two weeks MCD has been bumping up against a very solid wall of resistance. The $96.95 to ...
Texas Instruments is surging today. Shares are up over 2.7% and are moving further into new 52W high gro...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.